Download PDF
Pharmacopsychiatry 2015; 48(07): 256-264
DOI: 10.1055/s-0035-1559640
Review
© Georg Thieme Verlag KG Stuttgart · New York

The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective

A. G. Franke
1   Department of Social Work and Education, University of Neubrandenburg (University of Applied Sciences), Neubrandenburg, Germany
,
R. Northoff
1   Department of Social Work and Education, University of Neubrandenburg (University of Applied Sciences), Neubrandenburg, Germany
,
E. Hildt
2   Illinois Institute of Technology, Center for the Study of Ethics in the Professions, Chicago, USA
› Author Affiliations
Further Information

Publication History

received 03 February 2015
revised 09 July 2015

accepted 13 July 2015

Publication Date:
07 August 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Pharmacological neuroenhancement (PN) describes the use of psychoactive drugs for the purpose of enhancing cognition (e. g., fatigue, concentration, memory etc.) by healthy subjects without medical need. Drugs used for this purpose can be divided into freely available, over-the-counter drugs (e. g., methylxanthines such as caffeine), prescription drugs (e. g., antidementia drugs, methylphenidate) and illicit drugs (e. g., illicit amphetamines). Clinical studies have shown that the aforementioned substances only have limited pro-cognitive effects and have considerable safety risks and side effects.

The German judicial perspective shows legal differences between substances (drugs, food, food supplements, fortified food) that can be bought in a supermarket, drugs that can be bought in a pharmacy as over-the-counter- (OTC-) drugs, drugs with or without the need for a prescription and illicit drugs. Supermarket drugs and fortified food can be sold freely and follow the general rules of civil and penal law; regarding acquisition, parents are responsible for their children. OTC drugs require special information about therapy. Regarding prescription drugs, there are legal problems caused by an off-label use and the non-medical purposes of PN drugs. Furthermore, prescription stimulants for PN are governed by the specialized law for narcotics, and their use might be punished. Beyond the general lack of rules for regulation for PN drug use there are specific needs for prevention (e. g., control of the black market, etc.).

Possible future policy will depend, among others, on the probability with which effective PN drugs with an acceptable risk-benefit ratio will be available, on individual and societal implications, and on public opinion towards PN. While 4 different general policy scenarios can be identified, it is important to advance a broad societal debate on PN to collect relevant empirical data and to address enhancement-related conceptual issues.

Key words

cognitive enhancement - pharmacological neuroenhancement - legal - ethical/ethics
 

  • References

  • 1 Partridge BJ, Bell SK, Lucke JC et al. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS One 2011; 6: e28416
    CrossrefPubMedGoogle Scholar
  • 2 Chatterjee A. Cosmetic neurology: for physicians the future is now. Virtual Mentor 2004; 6
    PubMedGoogle Scholar
  • 3 Franke AG, Lieb K. Pharmacological neuroenhancement: substances and epidemiology. In: Hildt E, Franke AG. Cognitive enhancement – an interdisciplinary perspective. Heidelberg: Springer-Verlag; 2013: 17-27
    Google Scholar
  • 4 Lucke JC, Bell SK, Partridge BJ et al. Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals. EMBO Rep 2011; 12: 197-201
    CrossrefPubMedGoogle Scholar
  • 5 Muhammed K. Cosmetic neurology: the role of healthcare professionals. Med Health Care Philos 2014; 17: 239-240
    CrossrefPubMedGoogle Scholar
  • 6 Davis NJ. Neurodoping: brain stimulation as a performance-enhancing measure. Sports Med 2013; 43: 649-653
    CrossrefPubMedGoogle Scholar
  • 7 Franke AG, Lieb K. Pharmacological neuroenhancement and brain doping: Chances and risks. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53: 853-859
    Google Scholar
  • 8 Mehlman MJ. Cognition-enhancing drugs. Milbank Q 2004; 82: 483-506
    CrossrefPubMedGoogle Scholar
  • 9 Franke AG, Bagusat C, Rust S et al. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 2014; 264 (Suppl. 01) S83-S90
    PubMedGoogle Scholar
  • 10 Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 21-31
    Google Scholar
  • 11 Dietz P, Striegel H, Franke AG et al. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 2013; 33: 44-50
    CrossrefPubMedGoogle Scholar
  • 12 Franke AG, Bagusat C, Dietz P et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med 2013; 11: 102
    CrossrefPubMedGoogle Scholar
  • 13 Franke AG, Bagusat C, McFarlane C et al. The use of caffeinated substances by surgeons for cognitive enhancement. Ann Surg 2014; DOI: 10.1097/SLA.0000000000000830.
    PubMedGoogle Scholar
  • 14 Maher B. Poll results: look who’s doping. Nature 2008; 452: 674-675
    Google Scholar
  • 15 Deutsche Angestelltenkrankenkasse (DAK) . DAK-Gesundheitsreport 2015. Berlin: IGES Institut GmbH; 2015: 29-123
    Google Scholar
  • 16 Franke AG, Christmann M, Bonertz C et al. Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 44: 331-338
    Google Scholar
  • 17 Hildt E, Franke AG. Cognitive enhancement. An interdisciplinary perspective. Dordrecht: Springer-Verlag; 2013
    Google Scholar
  • 18 Solomon PR, Adams F, Silver A et al. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002; 288: 835-840
    CrossrefPubMedGoogle Scholar
  • 19 Kass LR. President’s Council: Biotechnology and the pursuit of happiness. A report of the President’s Council on Bioethics. Washington: 2003
    Google Scholar
  • 20 Miller KE. Wired: energy drinks, jock identity, masculine norms, and risk taking. J Am Coll Health 2008; 56: 481-489
    CrossrefPubMedGoogle Scholar
  • 21 Nestle M. Soft drink „pouring rights“: marketing empty calories to children. Public Health Rep 2000; 115: 308-319
    CrossrefPubMedGoogle Scholar
  • 22 Benowitz NL. Clinical pharmacology of caffeine. Annu Rev Med 1990; 41: 277-288
    CrossrefPubMedGoogle Scholar
  • 23 Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992; 17: 139-170
    Google Scholar
  • 24 Aggarwal R, Mishra A, Crochet P et al. Effect of caffeine and taurine on simulated laparoscopy performed following sleep deprivation. Br J Surg 2011; 98: 1666-1672
    CrossrefPubMedGoogle Scholar
  • 25 Killgore WD, Rupp TL, Grugle NL et al. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. J Sleep Res 2008; 17: 309-321
    CrossrefPubMedGoogle Scholar
  • 26 Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005; 14: 255-266
    Google Scholar
  • 27 Repantis D, Schlattmann P, Laisney O et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 2010; 62: 187-206
    Google Scholar
  • 28 Bagot KS, Kaminer Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 2014; 109: 547-557
    CrossrefPubMedGoogle Scholar
  • 29 Bukstein O. Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med 2008; 10: 24
    PubMedGoogle Scholar
  • 30 Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 2008; 24: 1345-1357
    CrossrefPubMedGoogle Scholar
  • 31 Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001; 68: 611-627
    CrossrefPubMedGoogle Scholar
  • 32 Kelley AM, Webb CM, Athy JR et al. Cognition enhancement by modafinil: a meta-analysis. Aviat Space Environ Med 2012; 83: 685-690
    CrossrefPubMedGoogle Scholar
  • 33 Hart CL, Haney M, Vosburg SK et al. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006; 31: 1526-1536
    CrossrefPubMedGoogle Scholar
  • 34 Sugden C, Housden CR, Aggarwal R et al. Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg 2012; 255: 222-227
    CrossrefPubMedGoogle Scholar
  • 35 Killgore WD, Kahn-Greene ET, Grugle NL et al. Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 2009; 32: 205-216
    Google Scholar
  • 36 Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010; 61: 473-481
    Google Scholar
  • 37 Franke AG, Lieb K, Fellgiebel A. From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr 2009; 77: 326-333
    Google Scholar
  • 38 Böllinger L. Drug law and policy in Germany and the European Community: Recent developments. J Drug Issues 2004; 34: 491
    CrossrefPubMedGoogle Scholar
  • 39 All German laws are published officially in the “Bundesgesetzblatt” (Bundesanzeiger Verlag GmbH, Köln). They are public knowledge and can be found on the internet www.gesetze-im-internet.de or published by eg Beck-Verlag, dtv, etc. Please note: German laws are presented in the following order: The law uses “Paragraph” (§) first, and then “Abschnitt”. To facilitate reading, this article replaces paragraph with the English translation section, then paragraph)
    PubMed
  • 40 Guidelines of the Gemeinsamen Bundesausschusses (G-BA) regarding regulations of prescription drugs (Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung, Arzneimittel-Richtlinie/AM-RL) (December 18, 2008/January 22, 2009 published in Bundesanzeiger 2009 Nr. 49a, last change March 22, 2014, published BAnz AT 11 August 2014 B2 effective 12 August 2014)
    PubMed
  • 41 McBride WG. Thalidomide and congenital abnormalities. The Lancet 1961; 2: 1358
    PubMedGoogle Scholar
  • 42 Deutsch E, Spickhoff AM. Medizinrecht, Arztrecht, Arzneimittelrecht, Medizinproduktrecht und Transfusionsrech. Berlin: Springer-Verlag; 2008
    Google Scholar
  • 43 Bundesverfassungsgericht (BVG) . Beschluss vom 9.3.1994. Strafverteidiger 1994; 295
    PubMedGoogle Scholar
  • 44 Whitehouse PJ, Juengst E, Mehlman M et al. Enhancing cognition in the intellectually intact. Hastings Cent Rep 1997; 27: 14-22
    PubMedGoogle Scholar
  • 45 Farah MJ, Illes J, Cook-Deegan R et al. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004; 5: 421-425
    Google Scholar
  • 46 Sententia W. Neuroethical considerations: cognitive liberty and converging technologies for improving human cognition. Ann N Y Acad Sci 2004; 1013: 221-228
    PubMedGoogle Scholar
  • 47 Bolt I, Schermer M. Psychopharmacological enhancers: enhancing identity?. Neuroethics 2008; 2: 103-111
    PubMedGoogle Scholar
  • 48 Glannon W. Psychopharmacological enhancement. Neuroethics 2008; 1: 45-54
    CrossrefPubMedGoogle Scholar
  • 49 Greely H, Sahakian B, Harris J et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456: 702-705
    Google Scholar
  • 50 Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics 2009; 15: 311-341
    CrossrefPubMedGoogle Scholar
  • 51 Bublitz JC, Merkel R. Autonomy and authenticity of enhanced personality traits. Bioethics 2009; 23: 360-374
    CrossrefPubMedGoogle Scholar
  • 52 Cakic V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 2009; 35: 611-615
    Google Scholar
  • 53 Metzinger T, Hildt E. Cognitive enhancement. In: Illes J, Sahakian BJ. The Oxford Handbook of Neuroethics. Oxford: Oxford University Press; 2011: 245-264
    CrossrefGoogle Scholar
  • 54 Juengst ET. What does enhancement mean?. In: Parens E. Enhancing human traits: Ethical and social implications. Washington DC: Georgetown University Press; 1998: 29-47
    Google Scholar
  • 55 Frankford DM. The treatment/enhancement distinction as an armament in the policy wars. In: Parens E. Enhancing human traits: Ethical and social implications. Washington DC: Georgetown University Press; 1998: 70-94
    Google Scholar
  • 56 Bostrom N, Roache R. Smart policy: Cognitive enhancement and the public interest. In: Savulescu J, ter Meulen R, Kahane G. Enhancing human capacities. London: Wiley-Blackwell; 2011: 138-149
    CrossrefGoogle Scholar
  • 57 Makridis C. Converging technologies: a critical analysis of cognitive enhancement for public policy application. Sci Eng Ethics 2013; 19: 1017-1038
    CrossrefPubMedGoogle Scholar
  • 58 Ragan CI, Bard I, Singh I et al. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 2013; 64: 588-595
    CrossrefPubMedGoogle Scholar
  • 59 Hildt E. Cognitive enhancement – a critical look at the recent debate. In: Hildt E, Franke AG. Cognitive enhancement. An interdisciplinary perspective. Dordrecht: Springer-Verlag; 2013: 1-14
    Google Scholar
  • 60 Heinz A, Kipke R, Heimann H et al. Cognitive neuroenhancement: false assumptions in the ethical debate. J Med Ethics 2012; 38: 372-375
    CrossrefPubMedGoogle Scholar
  • 61 Shaw DM. Neuroenhancers, addiction and research ethics. J Med Ethics 2012; 38: 605-608
    CrossrefPubMedGoogle Scholar
  • 62 Forlini C, Hall W, Maxwell B et al. Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. EMBO Rep 2013; 14: 123-128
    CrossrefPubMedGoogle Scholar
  • 63 Maslen H, Faulmuller N, Savulescu J. Pharmacological cognitive enhancement-how neuroscientific research could advance ethical debate. Front Syst Neurosci 2014; 8: 107
    PubMedGoogle Scholar
  • 64 Sarewitz D, Karas TH. Policy implications of technologies for cognitive enhancement. Sandia: Sandia Report, Sandia National Laboratories; 2007
    CrossrefGoogle Scholar
  • 65 Pustovrh T, Mali F. Exploring some challenges of the pharmacological cognitive enhancement discourse: users and policy recommendations. Neuroethics 2014; 7: 137-158
    CrossrefPubMedGoogle Scholar
  • 66 Forlini C, Racine E. Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Med Ethics 2009; 10: 9
    CrossrefPubMedGoogle Scholar
  • 67 Racine E, Forlini C. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethics blind spots in current debates. Neuroethics 2010; 3: 1-4
    CrossrefPubMedGoogle Scholar
  • 68 Metzinger TK. Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles. Fortschr Neurol Psychiatr 2012; 80: 36-43
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 European Commission. Options for Strengthening Responsible Research and Innovation. Report of the Expert Group on the State of Art in Europe on Responsible Research and Innovation. Brussels 2013
    PubMedGoogle Scholar
  • 70 von Schomberg R. A vision of responsible innovation. In: Owen R, Heintz M, Bessant J. Responsible Innovation. London: John Wiley; 2013
    CrossrefGoogle Scholar
  • 71 Outram SM, Racine E. Examining reports and policies on cognitive enhancement: approaches, rationale, and recommendations. Account Res 2011; 18: 323-341
    PubMedGoogle Scholar
  • 72 Schermer M, Bolt I, de Jongh R et al. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009; 2: 75-87
    CrossrefPubMedGoogle Scholar
  • 73 Kutschenko L. In quest of “good” medical classification systems. Med Studies 2011; 3: 53-70
    PubMedGoogle Scholar
  • 74 Schermer M, Bolt I, de Jongh R et al. The ruture of psychopharmacological enhancements: expectations and policies. Neuroethics 2009; 2: 75-87
    CrossrefPubMedGoogle Scholar
  • 75 Ferre S, Ciruela F, Borycz J et al. Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 2008; 13: 2391-2399
    CrossrefPubMedGoogle Scholar
  • 76 Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004; 61: 857-872
    Google Scholar
  • 77 Marley E, Nistico G. Effects of catecholamines and adenosine derivatives given into the brain of fowls. Br J Pharmacol 1972; 46: 619-636
    Google Scholar
  • 78 Oades RD, Sadile AG, Sagvolden T et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 2005; 8: 122-131
    Google Scholar
  • 79 Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol 2008; 28: S39-S45
    CrossrefPubMedGoogle Scholar
  • 80 Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008; 28: S46-S53
    CrossrefPubMedGoogle Scholar
  • 81 Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33: 1477-1502
    Google Scholar